EligibleTrials

Clinical trials recruiting for Squamous Cell Carcinoma of the Head and Neck

5
Recruiting trials
23
US states with sites
11
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 3Phase 2 2Not applicable 2

Drugs and treatments being studied

InterventionTrials
Pembrolizumab3
Modi-1 Moditope1
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]1
PF-080460541
ST-0671

Where trials are recruiting (top US states)

StateRecruiting trials
Alabama2
Arizona2
California2
Colorado2
Florida2
Massachusetts2
Michigan2
New York2
Ohio2
Texas2
Utah2
Arkansas1

Top cities

Birmingham, Alabama 2Boston, Massachusetts 2Cleveland, Ohio 2Dallas, Texas 2Sacramento, California 2San Antonio, Texas 2Appleton, Wisconsin 1Aurora, Colorado 1Broomall, Pennsylvania 1Buffalo, New York 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Squamous Cell Carcinoma of the Head and Neck often also study these conditions. Each links to its own recruiting-trial list.

Lung cancer 2180Breast cancer 2239Triple-negative breast cancer 138Renal cell carcinoma 28Pancreatic cancer 870Pancreatic Adenocarcinoma 49Non-small cell lung cancer 507Melanoma 487Colorectal cancer 1359Triple Negative Breast Neoplasms 12

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Squamous Cell Carcinoma of the Head and Neck trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.